PRVA

PRVA

USD

Privia Health Group Inc. Common Stock

$23.320+0.180 (0.778%)

Reaalajas hind

Healthcare
Health Information Services
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$23.140

Kõrge

$23.360

Madal

$23.000

Maht

0.06M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

2.8B

Tööstusharu

Health Information Services

Riik

United States

Kauplemisstatistika

Keskmine maht

0.83M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $15.92Praegune $23.320Kõrge $26.037

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 29. apr 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

PRVA (Privia Health Group Inc. Common Stock): Checking the Pulse on Recent Analyst Views and Price Action

Stock Symbol: PRVA Generate Date: 2025-04-29 18:57:51

Let's take a look at what's been happening with Privia Health Group lately, based on the latest news and how the stock price has been moving.

What Analysts Are Saying

The recent buzz around PRVA seems mostly positive, at least from the analyst crowd. We've seen a few different firms weigh in over the past month or so.

  • JMP Securities just recently (April 28th) stuck with their "Market Outperform" rating and kept their price target at a solid $29. That's a pretty strong vote of confidence.
  • Before that, Baird (April 15th) also kept their "Outperform" rating but actually bumped up their price target a bit, moving it from $24 to $26. That's another positive sign, showing they see more room for the stock to run.
  • Barclays (April 10th) maintained a more neutral "Equal-Weight" rating, but they did raise their price target from $21 to $23. So, even a more cautious view saw enough improvement to lift their target.
  • Also on April 10th, Truist Securities kept their "Buy" rating, though they slightly adjusted their target from $27 to $28. Still a "Buy," which is good.
  • Needham, also on April 10th, reiterated their "Buy" rating and held their price target steady at $30.

Putting it simply, the general feeling from these analysts is leaning positive. Most have a "Buy" or "Outperform" rating, and several have actually raised their price targets recently. This tells us that the pros who follow this company think things are heading in the right direction, or at least have potential.

How the Stock Price Has Been Acting

Looking back over the last month or so, the price of PRVA has seen a bit of a rollercoaster, but it seems to have found a recent range.

Back in late March and early April, the stock dipped down towards the $22 mark, even touching below that briefly. Then, around mid-April, right when some of that analyst news started hitting, the price bounced back up, climbing into the $24 range.

More recently, since about April 15th, the price has pulled back a little from those highs and seems to be trading mostly between $22.50 and $23.50. The last recorded price point shows it closing around $23.58.

So, we saw a dip, a bounce, and now it looks like it's consolidating or trading sideways in the low $23s.

What This Might Mean and Some Ideas

Okay, let's try to connect the dots. We have analysts who are mostly positive, raising targets, and a stock price that recently bounced but is now hanging around the $23-$23.50 area.

The AI prediction model also chimes in, suggesting small upward moves are likely in the very near term: predicting a tiny gain today (+0.34%), then slightly larger gains tomorrow (+2.44%) and the day after (+2.64%). This aligns with the generally positive analyst sentiment.

Based on this mix – positive analyst views, a recent price bounce, and AI predicting continued upward movement – the near-term picture seems to lean positive. It doesn't look like a runaway train right now, but the underlying sentiment and predictions suggest potential for the price to climb from here.

Potential Entry Consideration: If you were thinking about this stock, the current price area, around $23.58, could be a point to consider. It's right where the stock is trading now, and the AI sees it moving up from here. The AI's recommendation data also pointed to potential entry spots slightly lower, around $23.16 or $23.26. If the stock dips back towards that $23.20-$23.30 zone, that might also look interesting, as it's been a recent trading area.

Potential Exit/Stop-Loss Consideration: Managing risk is always smart. The AI recommendation data suggests a potential take-profit level around $24.63. This is above the recent trading range and could be a spot to consider if the stock climbs. For managing downside risk, the AI suggests a stop-loss at $20.90. This is well below recent lows and gives the stock plenty of room to move without triggering a stop unless there's a significant drop.

A Little About the Company

Just to add some context, Privia Health Group is in the Healthcare sector, specifically focusing on Health Information Services. They work with doctors, health plans, and hospitals, basically helping physician practices run better, use technology, and manage patient care more effectively, especially in value-based care models. The analyst views and price movements are likely tied to how well the market thinks they are executing on this strategy and growing their business in the healthcare space.


Disclaimer: This report is for informational purposes only and is based on the provided data. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research or consult with a qualified financial advisor before making any investment decisions.

Seotud uudised

Analyst Upgrades

JMP Securities Reiterates Market Outperform on Privia Health Gr, Maintains $29 Price Target

JMP Securities analyst Constantine Davides reiterates Privia Health Gr with a Market Outperform and maintains $29 price target.

Vaata rohkem
JMP Securities Reiterates Market Outperform on Privia Health Gr, Maintains $29 Price Target
Analyst Upgrades

Baird Maintains Outperform on Privia Health Gr, Raises Price Target to $26

Baird analyst Michael Ha maintains Privia Health Gr with a Outperform and raises the price target from $24 to $26.

Vaata rohkem
Baird Maintains Outperform on Privia Health Gr, Raises Price Target to $26
Analyst Upgrades

Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $23

Barclays analyst Andrew Mok maintains Privia Health Gr with a Equal-Weight and raises the price target from $21 to $23.

Vaata rohkem
Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $23
Analyst Upgrades

Truist Securities Maintains Buy on Privia Health Gr, Lowers Price Target to $28

Truist Securities analyst Jailendra Singh maintains Privia Health Gr with a Buy and lowers the price target from $27 to $28.

Vaata rohkem
Truist Securities Maintains Buy on Privia Health Gr, Lowers Price Target to $28
Analyst Upgrades

Needham Reiterates Buy on Privia Health Gr, Maintains $30 Price Target

Needham analyst Matthew Sheerin reiterates Privia Health Gr with a Buy and maintains $30 price target.

Vaata rohkem
Needham Reiterates Buy on Privia Health Gr, Maintains $30 Price Target

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 4. mai 2025, 01:58

LangevNeutraalneTõusev

72.5% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
Mõõdukas
Kauplemisjuhend

Sisenemispunkt

$23.29

Võta kasum

$23.78

Peata kahjum

$20.98

Põhitegurid

PDI 4.6 on MDI 3.4 kohal ADX-iga 18.9, mis viitab tõusutrendile
Praegune hind on tugitasemele ($23.27) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 5.1x keskmisest (8,275), mis viitab äärmiselt tugevale ostusurvele
MACD 0.0279 on signaalijoone 0.0248 kohal, mis viitab tõusvale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.